Document is current
Any future updates will be listed below
-
Authors
Kaplan, Sigal https://orcid.org/0000-0002-3352-8480
Zeygarnik, Mikhail https://orcid.org/0000-0002-6742-943X
Stern, Tal
-
Funding
Funding for this research was provided by:
Teva Pharmaceutical Industries
- License Information
-
More Information
Article History
Accepted: 23 February 2022
First Online: 16 March 2022
Declarations
:
: This analysis was funded by Teva Pharmaceutical Industries Ltd.
: Sigal Kaplan, Mikhail Zeygarnik, and Tal Stern are employees of Teva Pharmaceutical Industries Ltd.
: The analyses were conducted retrospectively as part of a regulatory commitment using de-identified patient data, and thus, were deemed exempt from ethics approval and informed consent was not required.
: Not applicable.
: Not applicable.
: The original contributions presented in the study are included in this published article and its supplementary information files.
: Not applicable.
: SK: study supervision, analysis, interpretation of data, drafting of manuscript. MZ: study supervision, analysis, interpretation of data. TS: data acquisition, analysis, interpretation of data. All authors reviewed and approved the final manuscript.
: The views expressed in this article are those of the authors and do not necessarily reflect those of Teva Pharmaceutical Industries Ltd. and/or its affiliates.
